Sebastián Giulianelli

Sebastián Giulianelli

Auto-generated profile, based on publicly available information

Sebastián Giulianelli

Instituto de Biología de Organismos Marinos, IBIOMAR (CCT CONICET-CENPAT), Puerto Madryn, Argentina

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2008 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LALourdes Arruvito
Lourdes Arruvito
SGSebastián Giulianelli
Sebastián Giulianelli
AFAna C. Flores
Ana C. Flores
NPNatalia Paladino
Natalia Paladino
MBMarcos Barboza
Marcos Barboza
LFLeonardo Fainboim
Leonardo Fainboim
It has been proposed that progesterone (P4) induces the suppression of immune responses, particularly during pregnancy. However, knowledge about the mechanisms involved has remained largely elusive. We demonstrate herein that peripheral blood NK (PBNK) cells express both classical progesterone receptor (PR) isoforms and are specifically affected by the actions of P4 through two apparently independent mechanisms. Progesterone induces caspase-dependent PBNK cell death, which is reversed by two different anti-progestins, ZK 98.299 and RU 486, supporting the involvement of classical PR isoforms. It was suggested that CD56brightCD16− killer Ig-like receptor (KIR)− NK cells might represent precursor cells, which, upon activation, acquire the features of a more mature NK subset expressing KIR receptors. The present study demonstrates that PR expression seems to be restricted to more mature KIR+ PBNK cells. The expression of PR had a functional counterpart in the suppressive effect of P4 on IL-12-induced IFN-γ secretion. This cytokine suppression was mainly observed in KIR+ PBNK cells, without affecting the high secretion of IFN-γ by CD56bright PBNK cells. The lack of PR expression on CD56brightKIR− PBNK cells provides an additional phenotypic marker to test the idea that they might represent the PBNK precursors selectively recruited into the endometrium where they differentiate to become the uterine NK cells. Additionally, these findings may be relevant to NK cell function in viral immunity, human reproduction, and tumor immunity.

30 April 2012 in Cancer Research
Verified
Journal Article
Open access
PDF file
SGSebastián Giulianelli
Sebastián Giulianelli
JVJosé Pedro Vaqué
José Pedro Vaqué
RSRocío Soldati
Rocío Soldati
VWVictoria Wargon
Victoria Wargon
SVSilvia I. Vanzulli
Silvia I. Vanzulli
CLClaudia Lanari
Claudia Lanari
Synthetic progesterone used in contraception drugs (progestins) can promote breast cancer growth, but the mechanisms involved are unknown. Moreover, it remains unclear whether cytoplasmic interactions between the progesterone receptor (PR) and estrogen receptor alpha (ERα) are required for PR activation. In this study, we used a murine progestin-dependent tumor to investigate the role of ERα in progestin-induced tumor cell proliferation. We found that treatment with the progestin medroxyprogesterone acetate (MPA) induced the expression and activation of ERα, as well as rapid nuclear colocalization of activated ERα with PR. Treatment with the pure antiestrogen fulvestrant to block ERα disrupted the interaction of ERα and PR in vitro and induced the regression of MPA-dependent tumor growth in vivo. ERα blockade also prevented an MPA-induced increase in CYCLIN D1 (CCND1) and MYC expression. Chromatin immunoprecipitation studies showed that MPA triggered binding of ERα and PR to the CCND1 and MYC promoters. Interestingly, blockade or RNAi-mediated silencing of ERα inhibited ERα, but not PR binding to both regulatory sequences, indicating that an interaction between ERα and PR at these sites is necessary for MPA-induced gene expression and cell proliferation. We confirmed that nuclear colocalization of both receptors also occurred in human breast cancer samples. Together, our findings argued that ERα–PR association on target gene promoters is essential for progestin-induced cell proliferation. Cancer Res; 72(9); 2416–27. ©2012 AACR.

1 June 2009 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
CLClaudia Lanari
Claudia Lanari
CLCaroline A Lamb
Caroline A Lamb
VFVictoria T Fabris
Victoria T Fabris
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
RSRocío Soldati
Rocío Soldati
AMAlfredo Molinolo
Alfredo Molinolo
More than 60% of all breast neoplasias are ductal carcinomas expressing estrogen (ER) and progesterone receptors (PR). By contrast, most of the spontaneous, chemically or mouse mammary tumor virus induced tumors, as well as tumors arising in genetically modified mice do not express hormone receptors. We developed a model of breast cancer in which the administration of medroxyprogesterone acetate to BALB/c female mice induces mammary ductal carcinomas with a mean latency of 52 weeks and an incidence of about 80%. These tumors are hormone-dependent (HD), metastatic, express both ER and PR, and are maintained by syngeneic transplants. The model has been further refined to include mammary carcinomas that evolve through different stages of hormone dependence, as well as several hormone-responsive cell lines. In this review, we describe the main features of this tumor model, highlighting the role of PR as a trigger of key signaling pathways mediating tumor growth. In addition, we discuss the relevance of this model in comparison with other presently used breast cancer models pointing out its advantages and limitations and how, this model may be suitable to unravel key questions in breast cancer.

2 September 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SGSebastián Giulianelli
Sebastián Giulianelli
JCJuan P. Cerliani
Juan P. Cerliani
CLCaroline A. Lamb
Caroline A. Lamb
VFVictoria T. Fabris
Victoria T. Fabris
MBMaría C. Bottino
María C. Bottino
CLClaudia Lanari
Claudia Lanari
The mechanisms by which mammary carcinomas acquire hormone independence are still unknown. To study the role of cancer‐associated fibroblasts (CAF) in the acquisition of hormone‐independence we used a hormone‐dependent (HD) mouse mammary tumor and its hormone‐independent (HI) variant, which grows in vivo without hormone supply. HI tumors express higher levels of FGFR‐2 than HD tumors. In spite of their in vivo differences, both tumors have the same hormone requirement in primary cultures. We demonstrated that CAF from HI tumors (CAF‐HI) growing in vitro, express higher levels of FGF‐2 than HD counterparts (CAF‐HD). FGF‐2 activated the progesterone receptors (PR) in the tumor cells, thus increasing cell proliferation in both HI and HD tumors. CAF‐HI induced a higher proliferative rate on the tumor cells and in PR activation than CAF‐HD. The blockage of FGF‐2 in the co‐cultures or the genetic or pharmacological inhibition of FGFR‐2 inhibited PR activation and tumor cell proliferation. Moreover, in vivo, the FGFR inhibitor decreased C4‐HI tumor growth, whereas FGF‐2 was able to stimulate C4‐HD tumor growth as MPA. T47D human breast cancer cells were also stimulated by progestins, FGF‐2 or CAF‐HI, and this stimulation was abrogated by antiprogestins, suggesting that the murine C4‐HI cells respond as the human T47D cells. In summary, this is the first study reporting differences between CAF from HD and HI tumors suggesting that CAF‐HI actively participate in driving HI tumor growth.

15 May 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJuan P. Cerliani
Juan P. Cerliani
TGTomás Guillardoy
Tomás Guillardoy
SGSebastián Giulianelli
Sebastián Giulianelli
JVJosé Pedro Vaqué
José Pedro Vaqué
JGJ.Silvio Gutkind
J.Silvio Gutkind
CLClaudia Lanari
Claudia Lanari
Fibroblast growth factor (FGF) receptor 2 (FGFR-2) polymorphisms have been associated with an increase in estrogen receptor and progesterone receptor (PR)-positive breast cancer risk; however, a clear mechanistic association between FGFR-2 and steroid hormone receptors remains elusive. In previous works, we have shown a cross talk between FGF2 and progestins in mouse mammary carcinomas. To investigate the mechanisms underlying these interactions and to validate our findings in a human setting, we have used T47D human breast cancer cells and human cancer tissue samples. We showed that medroxyprogesterone acetate (MPA) and FGF2 induced cell proliferation and activation of ERK, AKT, and STAT5 in T47D and in murine C4-HI cells. Nuclear interaction between PR, FGFR-2, and STAT5 after MPA and FGF2 treatment was also showed by confocal microscopy and immunoprecipitation. This effect was associated with increased transcription of PRE and/or GAS reporter genes, and of PR/STAT5-regulated genes and proteins. Two antiprogestins and the FGFR inhibitor PD173074, specifically blocked the effects induced by FGF2 or MPA respectively. The presence of PR/FGFR-2/STAT5 complexes bound to the PRE probe was corroborated by using NoShift transcription and chromatin immunoprecipitation of the MYC promoter. Additionally, we showed that T47D cells stably transfected with constitutively active FGFR-2 gave rise to invasive carcinomas when transplanted into NOD/SCID mice. Nuclear colocalization between PR and FGFR-2/STAT5 was also observed in human breast cancer tissues. This study represents the first demonstration of a nuclear interaction between FGFR-2 and STAT5, as PR coactivators at the DNA progesterone responsive elements, suggesting that FGFRs are valid therapeutic targets for human breast cancer treatment. Cancer Res; 71(10); 3720–31. ©2011 AACR.

1 November 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
VWVictoria Wargon
Victoria Wargon
MRMarina Riggio
Marina Riggio
SGSebastián Giulianelli
Sebastián Giulianelli
GSGonzalo R. Sequeira
Gonzalo R. Sequeira
PRPaola Rojas
Paola Rojas
CLClaudia Lanari
Claudia Lanari
There is emerging interest in understanding the role of progesterone receptors (PRs) in breast cancer. The aim of this study was to investigate the proliferative effect of progestins and antiprogestins depending on the relative expression of the A (PRA) and B (PRB) isoforms of PR. In mifepristone (MFP)‐resistant murine carcinomas antiprogestin responsiveness was restored by re‐expressing PRA using demethylating agents and histone deacetylase inhibitors. Consistently, in two human breast cancer xenograft models, one manipulated to overexpress PRA or PRB (IBH‐6 cells), and the other expressing only PRA (T47D‐YA) or PRB (T47D‐YB), MFP selectively inhibited the growth of PRA‐overexpressing tumors and stimulated IBH‐6‐PRB xenograft growth. Furthermore, in cells with high or equimolar PRA/PRB ratios, which are stimulated to proliferate in vitro by progestins, and are inhibited by MFP, MPA increased the interaction between PR and the coactivator AIB1, and MFP favored the interaction between PR and the corepressor SMRT. In a PRB‐dominant context in which MFP stimulates and MPA inhibits cell proliferation, the opposite interactions were observed. Chromatin immunoprecipitation assays in T47D cells in the presence of MPA or MFP confirmed the interactions between PR and the coregulators at the CCND1 and MYC promoters. SMRT downregulation by siRNA abolished the inhibitory effect of MFP on MYC expression and cell proliferation. Our results indicate that antiprogestins are therapeutic tools that selectively inhibit PRA‐overexpressing tumors by increasing the SMRT/AIB1 balance at the CCND1 and MYC promoters.